In particular, the National Comprehensive Cancer Network Guideline states that CDDP-based regimens are preferential in the treatment of patients with pancreatic cancer and known BRCA1/2 mutations [58]. The gene discussed is BRCA1; the disease is familial pancreatic carcinoma.